Form 4: Charles River Laboratories CEO James C. Foster Reports Stock Transactions

James C. Foster, Chairman, President, and CEO of Charles River Laboratories, reports acquisition and disposal of company stock on January 31, 2025.

Summary

• On January 31, 2025, James C. Foster, the Chairman, President, and CEO of Charles River Laboratories, reported transactions involving the company's common stock.
• Foster acquired 19,608 shares of common stock at $0 per share due to the achievement of performance goals related to performance share unit awards granted on May 27, 2022.
• He also disposed of 6,827 shares of common stock at a price of $165.57 per share.
• Following these transactions, Foster directly owns 197,564 shares of common stock.
• Foster also indirectly owns shares through various trusts and a GRAT (Grantor Retained Annuity Trust), including 4,048 shares from a 2022 GRAT, 9,793 shares from a 2023 GRAT, 20,000 shares from a 2024 GRAT, 230 shares by Trust, 750 shares by Trust, 2,250 shares by Trust, and 10,000 shares held by spouse.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports stock transactions. The acquisition due to performance goals is mildly positive, while the disposal is mildly negative, balancing out to a neutral overall sentiment.

Positives

• The acquisition of shares due to performance goals being met could be seen as a positive indicator of company performance.

Negatives

• The disposal of shares could be interpreted negatively, although it may be for personal financial management reasons.

Risks

• Significant stock transactions by key executives can sometimes create uncertainty in the market.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of performance share units suggests an expectation of continued performance.

Industry Context

Insider trading activity is always closely watched in the pharmaceutical and biotech industries, as it can provide insights into management's perspective on the company's prospects. This Form 4 filing is a routine disclosure, but the details of the transactions are relevant to investors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The details of the transactions (number of shares, price, and reason) are typical of executive compensation and stock management activities.
• Comparing Foster's holdings and transactions to those of executives at comparable companies like Labcorp (LH) or Quest Diagnostics (DGX) could provide additional context.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholder sentiment.

Key Dates